51 Quotes by Barbara Ryan

Three months ago, Wall Street was telling Pfizer to fold up its tent and go home. Now some of the things we've been waiting for are coming.

We're left with a company with a litany of problems and a management that has zero credibility. I think some heads will roll and they will be very vulnerable to take-out.

Wyeth is really standing out relative to its peers currently because it has a fairly young portfolio of new drugs,

There is a 10-year lag in R&D spending, ... The spending that they're doing today isn't going to be visible in terms of products for quite some time.

We believe Merck has put in place an aggressive, but achievable strategic plan.

Expectations are fairly low, and these companies will deliver results that are in-line, or slightly better than expectations.

Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.

Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.

You're going to see a much more transparent and humbled management team with a lot more detail and granularity on a whole lot of issues, which is not characteristic of Pfizer historically. They have heard their shareholders loud and clear and recognize that they need to be transparent and more visible.